Doctors Comments on Rimonabant - Acomplia®

Disclaimer: The medication here are registered trademarks of Sanofi-Aventis. We are not associated or affiliated with them in any way. Any information found here is provided for general informational purposes only and is not meant to substitute for the advice provided by your own physician or other medical professional. You should not use any of the information found here to diagnose or treat a health issue or disease or to prescribe any medication. Always seek medical advice from a medical doctor. Please read entire disclaimer.

Comments from health care professionals:

"Acomplia's been given to 13,000 people but you just don't completely know what happens when you give it to a million.''
Dr. Louis J. Aronne, New York Hospital - Cornell Medical Center, quoted on June 28, 2006 by Bloomberg

"If there was a pill available that was safe, effective and made it easy to lose any weight at all, there would be a truly massive market."
Dr. Steve Bloom, researcher at Imperial College in London, quoted on June 28, 2006 by Bloomberg

"We come up with new drugs on the drawing board all the time, but rarely do they work the way we think they will. This one did. I think the drug has incredible potential."
Dr. Elbert Glover of West Virginia University Medical School quoted in the August 14, 2004 issue of Newsweek.

"Lifestyle interventions including exercise, behavior modification and reduced caloric intake should be mainstays in the battle against obesity. Unfortunately, there is no quick fix."
Dr. JoAnne Foody, cardiologist at Yale University in New Haven, Connecticut, quoted on June 28, 2006 by Bloomberg.

"Rimonabant shows a substantial weight reduction, and if that's possible without side effects it could be promising. I have concerns about the idea you just buy a drug and that's it, buying weight reduction instead of changing lifestyle habits.''
Dr.Otto Smiseth, a professor of medicine at University of Oslo, quoted on August 29. 2004 by Bloomberg.

"It will be very widely prescribed if found safe and effective in the remaining trials that are due to come out over the next year or two."
Dr. Christopher Cannon, a cardiologist at Brigham and Women's Hospital in Boston and an associate professor of medicine at Harvard University, quoted on August 29. 2004 by Bloomberg.